MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

Clinical trial NCT03606538 · NOT_YET_RECRUITING

Trial details

NCT number: NCT03606538
Sponsor: Resilient Pharmaceuticals
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Pharmacokinetics Hepatic Impairment

Start date: 2026-03-29
Primary completion: 2028-12-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.